Home/Filings/4/0001610717-25-000052
4//SEC Filing

Wei Lin 4

Accession 0001610717-25-000052

CIK 0001628171other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 7:01 PM ET

Size

6.9 KB

Accession

0001610717-25-000052

Insider Transaction Report

Form 4
Period: 2025-03-01
Wei Lin
Chief Medical Officer
Transactions
  • Award

    Common Stock

    2025-03-0120,80091,651 total
  • Award

    Stock Option (Right to Buy)

    2025-03-01+72,80072,800 total
    Exercise: $40.74Exp: 2035-02-28Common Stock (72,800 underlying)
Footnotes (2)
  • [F1]Includes 70,750 restricted stock units.
  • [F2]One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2025 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Documents

1 file

Issuer

Revolution Medicines, Inc.

CIK 0001628171

Entity typeother

Related Parties

1
  • filerCIK 0001872772

Filing Metadata

Form type
4
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 7:01 PM ET
Size
6.9 KB